Suppression of super-enhancer-driven TAL1 expression by KLF4 in T-cell acute lymphoblastic leukemia
© 2023. The Author(s), under exclusive licence to Springer Nature Limited..
TAL1 is one of the most frequently dysregulated genes in T-ALL and is overexpressed in about 50% of T-ALL cases. One of the molecular mechanisms of TAL1 overexpression is abnormal mutations in the upstream region of the TAL1 promoter that introduce binding motifs for the MYB transcription factor. MYB binding at this location creates a 5' TAL1 super-enhancer (SE), which leads to aberrant expression of TAL1 and is associated with unfavorable clinical outcomes. Although targeting TAL1 is considered to be an attractive therapeutic strategy for patients with T-ALL, direct inhibition of transcription factors is challenging. Here, we show that KLF4, a known tumor suppressor in leukemic cells, suppresses SE-driven TAL1 expression in T-ALL cells. Mechanistically, KLF4 downregulates MYB expression by directly binding to its promoter and inhibits the formation of 5' TAL1 SE. In addition, we found that APTO-253, a small molecule inducer of KLF4, exerts an anti-leukemic effect by targeting SE-driven TAL1 expression in T-ALL cells. Taken together, our results suggest that the induction of KLF4 is a promising strategy to control TAL1 expression and could be a novel treatment for T-ALL patients with a poor prognosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Oncogene - 43(2024), 6 vom: 15. Feb., Seite 447-456 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Noura, Mina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
135471-20-4 |
|---|
| Anmerkungen: |
Date Completed 05.02.2024 Date Revised 06.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41388-023-02913-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365930326 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365930326 | ||
| 003 | DE-627 | ||
| 005 | 20240206232044.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41388-023-02913-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1282.xml |
| 035 | |a (DE-627)NLM365930326 | ||
| 035 | |a (NLM)38102337 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Noura, Mina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Suppression of super-enhancer-driven TAL1 expression by KLF4 in T-cell acute lymphoblastic leukemia |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.02.2024 | ||
| 500 | |a Date Revised 06.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Nature Limited. | ||
| 520 | |a TAL1 is one of the most frequently dysregulated genes in T-ALL and is overexpressed in about 50% of T-ALL cases. One of the molecular mechanisms of TAL1 overexpression is abnormal mutations in the upstream region of the TAL1 promoter that introduce binding motifs for the MYB transcription factor. MYB binding at this location creates a 5' TAL1 super-enhancer (SE), which leads to aberrant expression of TAL1 and is associated with unfavorable clinical outcomes. Although targeting TAL1 is considered to be an attractive therapeutic strategy for patients with T-ALL, direct inhibition of transcription factors is challenging. Here, we show that KLF4, a known tumor suppressor in leukemic cells, suppresses SE-driven TAL1 expression in T-ALL cells. Mechanistically, KLF4 downregulates MYB expression by directly binding to its promoter and inhibits the formation of 5' TAL1 SE. In addition, we found that APTO-253, a small molecule inducer of KLF4, exerts an anti-leukemic effect by targeting SE-driven TAL1 expression in T-ALL cells. Taken together, our results suggest that the induction of KLF4 is a promising strategy to control TAL1 expression and could be a novel treatment for T-ALL patients with a poor prognosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Basic Helix-Loop-Helix Transcription Factors |2 NLM | |
| 650 | 7 | |a T-Cell Acute Lymphocytic Leukemia Protein 1 |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins |2 NLM | |
| 650 | 7 | |a Transcription Factors |2 NLM | |
| 650 | 7 | |a TAL1 protein, human |2 NLM | |
| 650 | 7 | |a 135471-20-4 |2 NLM | |
| 700 | 1 | |a Matsuo, Hidemasa |e verfasserin |4 aut | |
| 700 | 1 | |a Yasuda, Takahiko |e verfasserin |4 aut | |
| 700 | 1 | |a Tsuzuki, Shinobu |e verfasserin |4 aut | |
| 700 | 1 | |a Kiyoi, Hitoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Hayakawa, Fumihiko |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncogene |d 1990 |g 43(2024), 6 vom: 15. Feb., Seite 447-456 |w (DE-627)NLM012595683 |x 1476-5594 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2024 |g number:6 |g day:15 |g month:02 |g pages:447-456 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41388-023-02913-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2024 |e 6 |b 15 |c 02 |h 447-456 | ||